All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-02-01T10:27:24.000Z

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?

By Alia Mohamed
Featured
Javier Briones
Feb 1, 2020
Share:

Bookmark this article

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Javier Briones from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, explains why we should use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma.

Javier Briones explains CAR T therapy for Non-Hodgkin lymphoma and B-cell malignancies have shown to be effective but this success has not translated to Hodgkin lymphoma. He discusses his new trial that will look into the generation of CAR products directed at CD30, that are rich in memory T cells with greater intratumor activity.

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?

More about...
Aggressive B-cell lymphomasCAR therapyCAR-T 2020Classical Hodgkin lymphomaHodgkin lymphoma

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

The NEUTRODIET trial: Is a protective diet necessary after SCT?

Here, we summarize new findings from the phase III NEUTRODIET trial. The trial revealed no significant difference in infection rates, feeding outcomes, or acute GvHD incidence between...

Jan 25, 2023
Add bookmark

The NEUTRODIET trial: Is a protective diet necessary after SCT?

Here, we summarize new findings from the phase III NEUTRODIET trial. The trial revealed no significant difference in infection rates,...

Jan 25, 2023
Add bookmark

Why do we need registries for patients treated with CAR T therapy?

In this video, Christian Chabannon, University of Aix-Marseille, Marseille, FR, explains why we need registries for patients treated with CAR T therapy.

Jan 30, 2020
Add bookmark

Why do we need registries for patients treated with CAR T therapy?

In this video, Christian Chabannon, University of Aix-Marseille, Marseille, FR, explains why we need registries for patients treated...

Jan 30, 2020

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox